TY - JOUR AB - Pancreatic cancer remains one of the leading causes of cancer‑related mortality worldwide. The role of p53 family isoforms in the pathogenesis of human cancer has been under the radar for decades, mainly due to the significant structural homology of p63 and p73 genes with the notorious p53 gene. Both p63 and p73 have two main isoforms, transactivating (TA) and deltaN (DN), each of which has been studied in normal and cancer cells. Although their role in cancer remains elusive and is tissue‑specific, the manner in which they act in pancreatic cancer is evident. As for p53, the mechanism of its gain‑of‑function activities in pancreatic cancer is now better understood. In this review, the role of each gene and their isoforms is discussed, as well as the possible therapeutic agents for pancreatic cancer. Currently, the science revolving around p53 family isoforms focuses on their specific roles. Thus, we propose that future research be directed at studying the interaction between the isoforms, as well as accelerating the assessment of potential therapeutic agents. AD - School of Health Sciences, Department of Applied Biomedical Science and Biotechnology, International Medical University, 126, Jalan Jalil Perkasa 19, Kuala Lumpur 57000, Malaysia AU - Jahedi,Hossein AU - Fahud,Aminath ,Luveysa AU - Lim,Chooi ,Ling DA - 2019/09/01 DO - 10.3892/wasj.2019.23 EP - 246 IS - 5 JO - World Acad Sci J KW - pancreatic cancer p53 p63 p73 chemoresistance PY - 2019 SN - 2632-2900 2632-2919 SP - 236 ST - Role of p53 family isoforms in enhancing aggressiveness and chemoresistance in pancreatic cancer (Review) T2 - World Academy of Sciences Journal TI - Role of p53 family isoforms in enhancing aggressiveness and chemoresistance in pancreatic cancer (Review) UR - https://doi.org/10.3892/wasj.2019.23 VL - 1 ER -